Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8719021 | 0.68 | — | — | |
| SCHEMBL29911548 | 0.67 | APAF1 (0.30) | APAF1TDP2NSD2HKDC1 | |
| SCHEMBL1405516 | 0.65 | ACHE (0.30) | — | |
| SCHEMBL18766357 | 0.65 | MAPT (0.34) | APAF1TDP2NSD2HKDC1 | |
| Hydrochloric Acid SCHEMBL3904361 | 0.64 | — | — | |
| SCHEMBL7412185 | 0.61 | — | — | |
| SCHEMBL19004321 | 0.61 | — | — | |
| SCHEMBL6129247 | 0.61 | MAPT (0.38) | APAF1TDP2NSD2HKDC1 | |
| SCHEMBL11579318 | 0.60 | MAPT (0.37) | APAF1TDP2NSD2HKDC1 | |
| SCHEMBL1752650 | 0.59 | CHRNB2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164978-A | Dihydroquinolizinone carboxylic acid compound and application thereof as TRPV4 channel inhibitor | 河北医科大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-118164978-A | Dihydroquinolizinone carboxylic acid compound and application thereof as TRPV4 channel inhibitor | 河北医科大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-110088103-B | Novel tetrahydropyridopyrimidine compounds for the treatment and prophylaxis of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-109863145-B | Novel tetrahydroisoquinoline and tetrahydronaphthyridine compounds for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110088104-B | Tetrahydropyridopyrimidine compounds for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3732177-B1 | DIHYDROPYRIMIDINYLTHIAZOLE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-11124495-B2 | Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection | HOFFMANN-LA ROCHE, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-10968218-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968217-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3535256-B1 | NOVEL TETRAHYDROISOQUINOLINES AND TERAHYDRONAPHTHYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-12-02 | — | — | EP | disclosed |
| US-9458153-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| CN-105899508-A | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | disclosed |
| WO-2015173164-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-19 | — | — | WO | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-6630488-B1 | Quinolizinones as integrin inhibitors | BIOCHEM PHARMA, INC. (CA) | 2003-10-07 | — | — | US | disclosed |
| EP-1115724-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | Shire Biochem Inc. (CA) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000017197-A1 | QUINOLIZINONES AS INTEGRIN INHIBITORS | BIOCHEM PHARMA INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968217-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | TPMT, DPYD, HAVCR2 | APAF1 2446/4885TDP2 1951/4885NSD2 333/4885 |
| US-11124495-B2 | Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection | HCCS, HAVCR2, ZC3HAV1 | APAF1 3864/4885TDP2 2855/4885NSD2 141/4885 |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | APAF1 2402/4885TDP2 4583/4885NSD2 743/4885 |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | APAF1 2402/4885TDP2 4583/4885NSD2 743/4885 |
| US-10968218-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, TPMT, TYMP | APAF1 2470/4885TDP2 1318/4885NSD2 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.